Alkermes ALKS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Aristada And Aristada Initio | $370.04M+6.9% | $346.19M+5.6% | $327.69M+8.5% | $302.05M+9.7% | |
| LYBALVI | $346.69M+23.8% | $280.03M+45.9% | $191.89M+99.8% | $96.02M+1,069% | |
| Vivitrol | $467.91M+2.3% | $457.32M+14.2% | $400.42M+5.5% | $379.48M+10.4% | |
| Accrued Sales Discounts Allowances And Reserves by Product | |||||
| Medicaid Rebate | $757.99M-9.2% | $834.82M+2.0% | $818.77M+0.6% | $813.84M— | |
| Medicare Part D | $91M+7.2% | $84.92M+12.9% | $75.18M+13.0% | $66.51M— | |
| Other | $85.27M+16.3% | $73.3M+48.1% | $49.49M+10.6% | $44.76M— | |
| Product Discounts | $68.58M+4.3% | $65.77M+3.2% | $63.71M+12.2% | $56.79M— | |
| Revenue by Geography | |||||
| Foreign Country Excluding Specified Country | $102.36M-30.0% | $146.18M-14.2% | $170.29M-4.3% | $177.98M-5.0% | |
| IE | $754K-41.7% | $1.29M+9.8% | $1.18M-35.5% | $1.83M-15.9% | |
| US | $1.37B-2.7% | $1.41B-5.5% | $1.49B+60.1% | $931.99M-5.3% | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest by Geography | |||||
| IE | $280.13M-36.4% | $440.67M+7.0% | $411.77M+1,379% | -$32.2M-138% | |
| US | $11.32M+268% | $3.08M-68.5% | $9.75M+811% | $1.07M-53.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
